Extended-Release Guaifenesin/Pseudoephedrine Hydrochloride for Symptom Relief in Support of a Wait-and-See Approach for the Treatment of Acute Upper Respiratory Tract Infections: A Randomized, Double-Blind, Placebo-Controlled Study

Edward J Septimus, Helmut H Albrecht, Gail Solomon, Tim Shea, Eric P Guenin, Edward J Septimus, Helmut H Albrecht, Gail Solomon, Tim Shea, Eric P Guenin

Abstract

Background: Despite the well-known fact that antibiotics (AB) are not effective against viruses, many patients ask for - and all too often doctors provide - AB for treating URTIs. Over-prescribing of AB is one of the key causes for the development of bacterial resistance, which the U.S. Centers for Disease Control and Prevention (CDC) calls "one of the world's most pressing public health problems". In addition to the CDC initiated "Get Smart About Antibiotics" campaign, focused on educating doctors the public about the importance of appropriate AB use, other programs tackling this problem include the development of new treatment paradigms. Data published at the Oregon Health & Science University demonstrated that a 'wait-and-see' approach, without an AB prescription for the treatment of acute childhood ear infections, was as quick, safe, and effective in resolving the infections as an AB prescription (Spiro DM, Tay KY, Arnold DH, Dziura JD, Baker MD, Shapiro ED. Wait-and-See Prescription for the Treatment of Acute Otitis Media. JAMA 2006; 296:1235-1241).

Objective: To try and reduce inappropriate prescribing practices, a wait and see or delayed approach requires patients to return for a prescription if their symptoms persist or worsen. The aim of this study was to determine whether treatment with Mucinex D (Reckitt Benckiser LLC, Parsippany, New Jersey) lowers the use of antibiotics in the treatment of URTIs when compared with placebo.

Methods: Patients aged 18 to 75 years with symptoms of acute URTIs were randomized to 1200 mg guaifenesin/120 mg pseudoephedrine hydrochloride extended-release, bilayer tablets or matching placebo for 7 consecutive days. Eligible patients met physician's criteria for antibiotic therapy but were considered suitable for a wait and see approach (withholding antibiotics for ≥48 hours). Patients recorded symptom ratings via an interactive voice response system.

Results: One thousand one hundred eighty-nine patients enrolled; data are presented for the modified intent-to-treat population (n = 1179). At Day 8, significantly fewer patients receiving guaifenesin/pseudoephedrine versus placebo desired antibiotics (4.2% vs 8.0%). No adverse effects were reported due to patients not taking antibiotics. Significant reductions in URTI symptoms were observed for extended-release guaifenesin/pseudoephedrine versus placebo, from Day 1 throughout the study; however, the proportion of patients experiencing overall relief at the Day 4 evening assessment (primary end point) did not reach statistical significance. Treatment-related adverse events were reported in 9.8% and 4.7% of patients receiving guaifenesin/pseudoephedrine and placebo, respectively.

Conclusions: The study found that a wait and see approach was associated with decreased antibiotic use. In addition, the use of a guaifenesin pseudoephedrine combination product provided an effective symptom control compared to a placebo and a well-tolerated first-line strategy for the management of URTIs. This study was not designed to assess the effects of guaifenesin or pseudoephedrine individually. Other limitations include the need for better clinical methods to assess the effectiveness of treatments for acute symptoms of patients with URTIs. ClinicalTrials.gov identifier: NCT01202279.

Keywords: antibiotics; extended-release guaifenesin; pseudoephedrine hydrochloride; upper respiratory tract infection.

Figures

Figure 1
Figure 1
Patient disposition. mITT = modified intent-to-treat.
Figure 2
Figure 2
Time point comparison of change from baseline in total symptom score (modified intent-to-treat population).
Figure 3
Figure 3
Percentage of patients requesting antibiotics at Day 4 and Day 8 (modified intent-to-treat population).
Figure 4
Figure 4
Patients’ end of treatment (Day 8) assessment of study medication (modified intent-to-treat population).

References

    1. Gonzales R., Bartlett J.G., Besser R.E., Hickner J.M., Hoffman J.R., Sande M.A. Principles of appropriate antibiotic use for treatment of nonspecific upper respiratory tract infections in adults: background. Ann Intern Med. 2001;134:490–494.
    1. Roumie C.L., Halasa N.B., Grijalva C.G., Edwards K.M., Zhu Y., Dittus R.S. Trends in antibiotic prescribing for adults in the United States – 1995 to 2002. J Gen Intern Med. 2005;20:697–702.
    1. Kelly C.P., LaMont J.T. Clostridium difficile — more difficult than ever. N Engl J Med. 2008;359:1932–1940.
    1. Fleming-Dutra K.E., Hersh A.L., Shapiro D.J., Bartoces M., Enns E.A., File T.M., Jr Prevalence of Inappropriate Antibiotic Prescriptions Among US Ambulatory Care Visits, 2010-2011. JAMA. 2016;315:1864–1873.
    1. Get Smart: Know When Antibiotics Work. . Accessed January 2013.
    1. Spiro D.M., Tay K.Y., Arnold D.H., Dziura J.D., Baker M.D., Shapiro E.D. Wait-and-see prescription for the treatment of acute otitis media: a randomized controlled trial. JAMA. 2006;296:1235–1241.
    1. Mucinex D NDA Dossier at Drugs@FDA Website. Accessed September 2016.
    1. Dicpinigaitis P.V., Gayle Y.E. Effect of guaifenesin on cough reflex sensitivity. Chest. 2003;124:2178–2181.
    1. Yuta A., Baraniuk J.N. Therapeutic approaches to mucus hypersecretion. Curr Allergy Asthma Rep. 2005;5:243–251.
    1. Robinson R.E., Cummings W.B., Deffenbaugh E.R. Effectiveness of guaifenesin as an expectorant: a cooperative double-blind study. Curr Ther Res Clin Exp. 1977;22:284–296.
    1. Storms W., Farrar J.R. Guaifenesin in rhinitis. Curr Allergy Asthma Rep. 2009;9:101–106.
    1. Scarupa M.D., Kaliner M.A. Adjuvant therapies in the treatment of acute and chronic rhinosinusitis. Clin Allergy Immunol. 2007;20:251–262.
    1. Becker D.G. Medical treatment of sinusitis. J Long Term Eff Med Implants. 2003;13:195–205.
    1. Eccles R., Jawad M.S., Jawad S.S., Angello J.T., Druce H.M. Efficacy and safety of single and multiple doses of pseudoephedrine in the treatment of nasal congestion associated with common cold. Am J Rhinol. 2005;19:25–31.
    1. LaForce C., Gentile D.A., Skoner D.P. A randomized, double-blind, parallel-group, multicenter, placebo-controlled study of the safety and efficacy of extended-release guaifenesin/pseudoephedrine hydrochloride for symptom relief as an adjunctive therapy to antibiotic treatment of acute respiratory infections. Postgrad Med. 2008;120:53–59.
    1. Albrecht H. Can Big Data Analyses Help Speed Up the Clinical Development of Mucoactive Drugs for Symptomatic RTIs? Lung. 2016;194:31–34.
    1. Barrett B., Brown R., Mundt M. Comparison of anchor-based and distributional approaches in estimating important difference in common cold. Qual Life Res. 2008;17:75–85.
    1. Barrett B., Harahan B., Brown D., Zhang Z., Brown R. Sufficiently Important Difference for Common Cold: Severity Reduction. Ann Fam Med. 2007;5:216–223.
    1. Rubin B.K. An in vitro comparison of the mucoactive properties of guaifenesin, iodinated glycerol, surfactant, and albuterol. Chest. 1999;116:195–200.
    1. Smith S.M., Schroeder K., Fahey T. Over-the-counter (OTC) medications for acute cough in children and adults in ambulatory settings. Cochrane Database Syst Rev. 2012;8 CD001831.
    1. Barrett B., Brown R., Mundt M., Safdar N., Dye L., Maberry R. The Wisconsin upper respiratory symptom survey is responsive, reliable, and valid. J Clin Epidemiol. 2005;58:609–617.
    1. Doyle W.J., Cohen S. Common cold. In: Eccles R., Weber O., editors. Etiology of the common cold: Modulating factors. Birkenhäuser Verlag; Basel: 2009. pp. 149–186.
    1. Eccles R. The powerful placebo in cough studies? Pulm Pharmacol Ther. 2002;15:303–308.
    1. McCambridge J., Witton J., Elbourne D.R. Systematic review of the Hawthorne effect: New concepts are needed to study research participation effects. J Clin Epidemiol. 2014;67:267–277.
    1. Taverner D., Latte G.J. Nasal decongestants for the common cold. Cochrane Database Syst Rev. 2007;1 CD001953.
    1. Wawrose S.F., Tami T.A., Amoils C.P. The role of guaifenesin in the treatment of sinonasal disease in patients infected with the human immunodeficiency virus (HIV) Laryngoscope. 1992;102:1225–1228.
    1. Rosen E.J., Calhoun K.H. Alterations of nasal mucociliary clearance in association with HIV infection and the effect of guaifenesin therapy. Laryngoscope. 2005;115:27–30.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel